Analytical Data
-
基因名
RANKL/TNFSF11
-
简介
RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, Fc) is a recombinant human RANKL (G63-D244) with N-terminal mFc tag, which is produced in HEK293 cell[1][2].
- Application
-
生物活性
1.The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells and the ED50 is ≤45 ng/mL. 2. Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF11B His at 2 μg/mL (100 μl/well) can bind Human RANKL mFc, the EC50 of Human RANKL mFc is 15-80 ng/mL. 3. Measured by its ability to induce osteoclast differentiation of RAW 264.7 cells. The ED50 for this effect is <12 ng/mL. Measured by its ability to induce osteoclast differentiation of RAW 264.7 cells. The ED50 for this effect is 8.696 ng/mL, corresponding to a specific activity is 1.150×10^5 U/mg.
-
别名
Tumor necrosis factor ligand superfamily member 11; ODF; RANKL; CD254; TNFSF11
-
种属
Human
-
表达系统
HEK293
-
标签
N-mFc
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
O14788-2
-
表达区间
G63-D244
-
蛋白长度
Full Length of Mature Protein
-
分子量
50-65 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RANKL (Receptor Activator of Nuclear Factor κB Ligand), also known as TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), plays a crucial role in bone metabolism and immune response. It is a cytokine that primarily regulates osteoclastogenesis—the process by which bone-resorbing osteoclasts are formed from precursor cells. The interaction of RANKL with its receptor RANK, found on osteoclast precursors, is fundamental for the differentiation, activation, and survival of osteoclasts, which are essential for bone remodeling. Dysregulation of the RANKL/RANK signaling pathway is implicated in various bone diseases, such as osteoporosis, rheumatoid arthritis, and bone metastasis. Research on recombinant RANKL protein has gained prominence as it provides vital insights into the molecular mechanisms of osteoclastogenesis and offers potential therapeutic avenues for treating bone-related disorders. Additionally, recombinant RANKL is used in in vitro studies to generate osteoclasts for research purposes, enhancing our understanding of bone biology and the pathophysiology of osteoclast-mediated diseases. The study of RANKL/TNFSF11 recombinant proteins could lead to innovative treatments that target RANKL signaling, potentially ameliorating conditions characterized by excessive bone loss or insufficient bone remodeling. As research progresses, elucidating the structure-function relationships, regulatory mechanisms, and therapeutic implications of RANKL will be pivotal in developing effective strategies for managing bone-related illnesses and improving patient outcomes.
